Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Biotechnol Bioeng ; 87(3): 400-12, 2004 Aug 05.
Article in English | MEDLINE | ID: mdl-15281114

ABSTRACT

An affinity chromatography step was developed for purification of recombinant B-Domain Deleted Factor VIII (BDDrFVIII) using a peptide ligand selected from a phage display library. The peptide library had variegated residues, contained both within a disulfide bond-constrained ring and flanking the ring. The peptide ligand binds to BDDrFVIII with a dissociation constant of approximately 1 microM both in free solution and when immobilized on a chromatographic resin. The peptide is chemically synthesized and the affinity resin is produced by coupling the peptide to an agarose matrix preactivated with N-hydroxysuccinimide. Coupling conditions were optimized to give consistent and complete ligand incorporation and validated with a robustness study that tested various combinations of processing limits. The peptide affinity chromatographic operation employs conditions very similar to an immunoaffinity chromatography step currently in use for BDDrFVIII manufacture. The process step provides excellent recovery of BDDrFVIII from a complex feed stream and reduces host cell protein and DNA by 3-4 logs. Process validation studies established resin reuse over 26 cycles without changes in product recovery or purity. A robustness study using a factorial design was performed and showed that the step was insensitive to small changes in process conditions that represent normal variation in commercial manufacturing. A scaled-down model of the process step was qualified and used for virus removal studies. A validation package addressing the safety of the leached peptide included leaching rate measurements under process conditions, testing of peptide levels in product pools, demonstration of robust removal downstream by spiking studies, end product testing, and toxicological profiling of the ligand. The peptide ligand affinity step was scaled up for cGMP production of BDDrFVIII for clinical trials.


Subject(s)
Chromatography, Affinity/methods , Chromatography, Agarose/methods , Factor VIII/chemistry , Factor VIII/isolation & purification , Peptides/chemistry , Animals , CHO Cells , Chromatography, Affinity/instrumentation , Chromatography, Agarose/instrumentation , Complex Mixtures/chemistry , Complex Mixtures/isolation & purification , Cricetinae , Cricetulus , Cyclic GMP/chemistry , Factor VIII/genetics , Humans , Ligands , Peptide Library , Protein Binding , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Virion/chemistry , Virion/isolation & purification
2.
J Chromatogr A ; 1038(1-2): 121-30, 2004 Jun 04.
Article in English | MEDLINE | ID: mdl-15233528

ABSTRACT

Polypeptides for use in affinity chromatography of factor VIII were identified using phage display technology. Phage libraries were designed to express polypeptide fusions containing five to seven residues flanked by two cysteines that form a disulfide bond. Individual bacteriophage were selected for the ability of these polypeptides to bind factor VIII, and then release the protein under mild elution conditions. Strong consensus sequences were observed that appear to be necessary for this reversible interaction. Chemically synthesized ligands identified by this screening were immobilized onto a chromatographic support and used for affinity purification of factor VIII from a complex feedstream. A chromatographic step was developed that provided a 10000-fold reduction in host cell proteins and DNA, while providing exceptional product recovery.


Subject(s)
Bacteriophages/genetics , Chromatography, Affinity/methods , Factor VIII/isolation & purification , Peptides/chemistry , Factor VIII/genetics
SELECTION OF CITATIONS
SEARCH DETAIL